# A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Source: https://onco.cc/trials/nct05625399/  
OnCo record `nct05625399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab, Relatlimab + nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma is a phase 3 interventional study registered as NCT05625399 by Bristol-Myers Squibb, with 579 participants enrolled, started 2023-03-06 and due to reach its primary completion in 2025-08-04. Interventions recorded: Nivolumab + Relatlimab, rHuPH20. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05625399
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
- Sponsor: Bristol-Myers Squibb
- Enrolled: 579

## Sources

- ClinicalTrials.gov NCT05625399: https://clinicaltrials.gov/study/NCT05625399

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05625399.json